Hospital Clinico Universitario Virgen Of Victoria

Málaga, Spain

Hospital Clinico Universitario Virgen Of Victoria

Málaga, Spain

Time filter

Source Type

Barja-Fernandez S.,Complejo Hospitalario | Barja-Fernandez S.,University of Santiago de Compostela | Barja-Fernandez S.,Instituto Salud Carlos III | Folgueira C.,Complejo Hospitalario | And 33 more authors.
Journal of Clinical Endocrinology and Metabolism | Year: 2015

Context: Betatrophin is produced primarily by liver and adipose tissue and has been recently reported as a novel hormone promoting β-cell proliferation and β-cell mass and improving glucose tolerance. Objective: Because it is markedly regulated by nutritional status, we hypothesized that circulating betatrophin levels might be affected by pathophysiological conditions altering body weight. Setting and Patients:Weanalyzed circulating betatrophin levels in 149 female patients, including 99 with extreme body mass index (30 anorexia nervosa, 24 obese, 45 morbid obese, and 50 healthy eating/weight controls). Outcome Measurements: Serum betatrophin levels and its correlations with different anthropometric and biochemical parameters were measured. Results: Plasma betatrophin levels were significantly elevated in anorexic patients, whereas its levels were reduced in morbidly obese women when compared with normal-weight women. Plasma betatrophin correlated negatively with weight, body mass index, fat percentage, glucose, insulin, and homeostatic model assessment index and positively correlated with high-density lipoprotein. Conclusions: These results suggest that metabolic status is an important regulator of circulating betatrophin levels. Copyright © 2015 by the Endocrine Society.


Pastor A.,Integrative Pharmacology and Systems Neuroscience Research Group | Pastor A.,University of Barcelona | Pastor A.,CIBER ISCIII | Fernandez-Aranda F.,University of Barcelona | And 23 more authors.
PLoS ONE | Year: 2016

The endocannabinoid (eCB) system can promote food intake by increasing odor detection in mice. The eCB system is over-active in human obesity. Our aim is to measure circulating eCB concentrations and olfactory capacity in a human sample that includes people with obesity and explore the possible interaction between olfaction, obesity and the eCB system. The study sample was made up of 161 females with five groups of body mass index subcategories ranging from under-weight to morbidly obese.We assessed olfactory capacity with the "SniffińSticks" test, which measures olfactory threshold-discrimination-identification (TDI) capacity.We measured plasma concentrations of the eCBs 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine or anandamide (AEA), and several eCBrelated compounds, 2-acylglycerols and N-acylethanolamines. 2-AG and other 2-acylglycerols fasting plasma circulating plasma concentrations were higher in obese and morbidly obese subjects. AEA and other N-acylethanolamine circulating concentrations were lower in under-weight subjects. Olfactory TDI scores were lower in obese and morbidly obese subjects. Lower TDI scores were independently associated with higher 2-AG fasting plasma circulating concentrations, higher %body fat, and higher body mass index, after controllingfor age, smoking, menstruation, and use of contraceptives. Our results show that obese subjects have a lower olfactory capacity than non-obese ones and that elevated fasting plasma circulating 2-AG concentrations in obesity are linked to a lower olfactory capacity. In agreement with previous studies we show that eCBs AEA and 2-AG, and their respective congeners have a distinct profile in relation to body mass index. The present report is the first study in humans in which olfactory capacity and circulating eCB concentrations have been measured in the same subjects. © 2016 Pastor et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Villarejo C.,University of Barcelona | Jimenez-Murcia S.,University of Barcelona | Jimenez-Murcia S.,CIBER ISCIII | Alvarez-Moya E.,CIBER ISCIII | And 25 more authors.
European Eating Disorders Review | Year: 2014

Goals This study aimed to analyse the association, commonalities and differences between obesity and eating disorders (ED). Method A total of 150 female patients [50 obese with bulimia nervosa (OB + BN), 50 obese with binge eating disorders (OB + BED), 50 obese without eating disorders (OB)] and 50 female healthy-eating/weight control (CG) volunteers participated in this study. Assessment All participants were assessed by the Eating Disorders Inventory-2 (EDI-2), the Symptom Checklist-Revised (SCL-90-R) and the Temperament and Character Inventory-Revised. Results In general, all the groups differed significantly and showed linear trends (OB + BN > OB + BED > OB > CG) on general and eating psychopathology (SCL-90-R and EDI-2). Regarding personality traits, statistically significant differences across all four groups were found on Harm Avoidance and Self-Directedness. Whereas some symptoms were shared in extreme weight conditions, others were specifically related to ED. Conclusions The presence of binge and purge symptomatology in obese patients is clinically relevant. These findings help to understand the relationship between Obesity and ED. Copyright © 2013 John Wiley & Sons, Ltd and Eating Disorders Association. Copyright © 2013 John Wiley & Sons, Ltd and Eating Disorders Association.


Villarejo C.,University of Barcelona | Fernandez-Aranda F.,University of Barcelona | Fernandez-Aranda F.,CIBER ISCIII | Jimenez-Murcia S.,University of Barcelona | And 23 more authors.
European Eating Disorders Review | Year: 2012

Objectives: The aims of our study were to examine the lifetime prevalence of obesity rate in eating disorders (ED) subtypes and to examine whether there have been temporal changes among the last 10years and to explore clinical differences between ED with and without lifetime obesity. Methods: Participants were 1383 ED female patients (DSM-IV criteria) consecutively admitted, between 2001 and 2010, to Bellvitge University Hospital. They were assessed by means of the Eating Disorders Inventory-2, the Symptom Checklist-90-Revised, the Bulimic Investigatory Test Edinburgh and the Temperament and Character Inventory-Revised. Results: The prevalence of lifetime obesity in ED cases was 28.8% (ranging from 5% in anorexia nervosa to 87% in binge-eating disorders). Over the last 10years, there has been a threefold increase in lifetime obesity in ED patients (p<.001). People with an ED and obesity had higher levels of childhood and family obesity (p<.001), a later age of onset and longer ED duration; and had higher levels of eating, general and personality symptomatology. Conclusions: Over the last 10years, the prevalence of obesity associated with disorders characterized by the presence of binge episodes, namely bulimic disorders, is increasing, and this is linked with greater clinical severity and a poorer prognosis. Copyright © 2012 John Wiley & Sons, Ltd and Eating Disorders Association.


Fagundo A.B.,University of Barcelona | de la Torre R.,CIBER ISCIII | de la Torre R.,IMIM Hospital del Mar Research Institute | Jimenez-Murcia S.,University of Barcelona | And 27 more authors.
PLoS ONE | Year: 2012

Background: Extreme weight conditions (EWC) groups along a continuum may share some biological risk factors and intermediate neurocognitive phenotypes. A core cognitive trait in EWC appears to be executive dysfunction, with a focus on decision making, response inhibition and cognitive flexibility. Differences between individuals in these areas are likely to contribute to the differences in vulnerability to EWC. The aim of the study was to investigate whether there is a common pattern of executive dysfunction in EWC while comparing anorexia nervosa patients (AN), obese subjects (OB) and healthy eating/weight controls (HC). Methods: Thirty five AN patients, fifty two OB and one hundred thirty seven HC were compared using the Wisconsin Card Sorting Test (WCST); Stroop Color and Word Test (SCWT); and Iowa Gambling Task (IGT). All participants were female, aged between 18 and 60 years. Results: There was a significant difference in IGT score (F(1.79); p<.001), with AN and OB groups showing the poorest performance compared to HC. On the WCST, AN and OB made significantly more errors than controls (F(25.73); p<.001), and had significantly fewer correct responses (F(2.71); p<.001). Post hoc analysis revealed that the two clinical groups were not significantly different from each other. Finally, OB showed a significant reduced performance in the inhibition response measured with the Stroop test (F(5.11); p<.001) compared with both AN and HC. Conclusions: These findings suggest that EWC subjects (namely AN and OB) have similar dysfunctional executive profile that may play a role in the development and maintenance of such disorders. © 2012 Fagundo et al.


Sauchelli S.,University of Barcelona | Sauchelli S.,CIBER ISCIII | Jimenez-Murcia S.,University of Barcelona | Jimenez-Murcia S.,CIBER ISCIII | And 40 more authors.
Psychoneuroendocrinology | Year: 2016

Background and aims: Orexins/hypocretins are orexigenic peptides implicated in the regulation of feeding behavior and the sleep/wake cycle. Little is known about the functioning of these peptides in anorexia nervosa (AN). The aims of the current study were to evaluate the extent to which orexin-might be linked to sleep and treatment outcome in AN. Method: Fasting plasma orexin-concentrations were measured in 48 females with AN at the start of a day hospital treatment and in 98 normal-eater/healthy-weight controls. The Pittsburgh Sleep Quality Index was administered at the beginning of the treatment as a measure of sleep quality. Other psychopathological variables were evaluated with the Symptom Checklist-Revised (SCL90R) and the Eating Disorder Inventory-(EDI). Patients were assessed at the start and end of treatment by means of commonly used diagnostic criteria and clinical questionnaires. Results: The AN patients presented more sleep disturbances and poorer overall sleep quality than did the healthy controls (= .026) but there were no global differences between groups in plasma orexin-concentrations (= .071). In the AN sample, orexin-concentrations were associated with greater sleep disturbances (|r| = .30), sleep inefficiency (|r| = .22) and poorer overall sleep (|r| = .22). Structural Equation Modeling (SEM) showed that both elevated orexin-concentrations and inadequate sleep predicted poorer treatment outcome. Conclusion: Plasma orexin-concentrations contribute to poor sleep quality in AN, and both of these variables are associated with therapy response. © 2015 Elsevier Ltd.


Mallorqui-Bague N.,University of Barcelona | Mallorqui-Bague N.,CIBER ISCIII | Fagundo A.B.,University of Barcelona | Fagundo A.B.,CIBER ISCIII | And 33 more authors.
PLoS ONE | Year: 2016

Introduction Addictions are associated with decision making impairments. The present study explores decision making in Substance use disorder (SUD), Gambling disorder (GD) and Obesity (OB) when assessed by Iowa Gambling Task (IGT) and compares them with healthy controls (HC). Methods For the aims of this study, 591 participants (194 HC, 178 GD, 113 OB, 106 SUD) were assessed according to DSM criteria, completed a sociodemographic interview and conducted the IGT. Results SUD, GD and OB present impaired decision making when compared to the HC in the overall task and task learning, however no differences are found for the overall performance in the IGT among the clinical groups. Results also reveal some specific learning across the task patterns within the clinical groups: OB maintains negative scores until the third set where learning starts but with a less extend to HC, SUD presents an early learning followed by a progressive although slow improvement and GD presents more random choices with no learning. Conclusions Decision making impairments are present in the studied clinical samples and they display individual differences in the task learning. Results can help understanding the underlying mechanisms of OB and addiction behaviors as well as improve current clinical treatments. © 2016 Mallorquí-Bagué et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Fernandez-Aranda F.,University of Barcelona | Fernandez-Aranda F.,CIBER ISCIII | Sauchelli S.,University of Barcelona | Pastor A.,CIBER ISCIII | And 34 more authors.
PLoS ONE | Year: 2014

Background: Endocannabinoids and temperament traits have been linked to both physical activity and body mass index (BMI) however no study has explored how these factors interact in females. The aims of this cross-sectional study were to 1) examine differences among distinct BMI groups on daytime physical activity and time spent in moderate-vigorous physical activity (MVPA), temperament traits and plasma endocannabinoid concentrations; and 2) explore the association and interaction between MVPA, temperament, endocannabinoids and BMI. Methods: Physical activity was measured with the wrist-worn accelerometer Actiwatch AW7, in a sample of 189 female participants (43 morbid obese, 30 obese, and 116 healthy-weight controls). The Temperament and Character Inventory-Revised questionnaire was used to assess personality traits. BMI was calculated by bioelectrical impedance analysis via the TANITA digital scale. Blood analyses were conducted to measure levels of endocannabinoids and endocannabinoid-related compounds. Path-analysis was performed to examine the association between predictive variables and MVPA. Results: Obese groups showed lower MVPA and dysfunctional temperament traits compared to healthy-weight controls. Plasma concentrations of 2-arachidonoylglyceryl (2-AG) were greater in obese groups. Path-analysis identified a direct effect between greater MVPA and low BMI (b = -0.13, p = .039) and high MVPA levels were associated with elevated anandamide (AEA) levels (b = 0.16, p = .049) and N-oleylethanolamide (OEA) levels (b = 0.22, p = .004), as well as high Novelty seeking (b = 0.18, p<.001) and low Harm avoidance (b = -0.16, p<.001). Conclusions: Obese individuals showed a distinct temperament profile and circulating endocannabinoids compared to controls. Temperament and endocannabinoids may act as moderators of the low MVPA in obesity. © 2014 Fernández-Aranda et al.

Loading Hospital Clinico Universitario Virgen Of Victoria collaborators
Loading Hospital Clinico Universitario Virgen Of Victoria collaborators